Atea Pharmaceuticals, Inc. (AVIR) Q4 2024 Annual Earnings
AVIR·Reported March 6, 2025·After market close
Diluted EPS came in at $-0.40, missed the $-0.35 consensus by $0.05.
Diluted EPS
$-0.40missed by $0.05
Consensus: $-0.35
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Atea Pharmaceuticals, Inc.'s Q4 2024 earnings report.
Atea Pharmaceuticals, Inc. (AVIR) reported Q4 2024 earnings on March 6, 2025 after market close.
Atea Pharmaceuticals, Inc. reported diluted EPS of $-0.40 for Q4 2024.
EPS missed the consensus estimate of $-0.35 by $0.05.
You can read the 10-K periodic report (0000950170-25-034808) directly on SEC EDGAR. The filing index links above go to sec.gov.